Leukemia Patents (Class 514/19.6)
-
Patent number: 8551951Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.Type: GrantFiled: January 22, 2010Date of Patent: October 8, 2013Assignee: Aenorasis SA Pharmaceuticals and Medical DevicesInventors: Seema Garde, Chandra J. Panchal, Madhulika Baijal-Gupta, Jennifer Fraser, Salam Kadhim
-
Publication number: 20130252905Abstract: Provided is a multimeric peptide comprising at least two peptide monomers linked to one another, each of the at least two peptide monomers comprising at least 6 consecutive amino acids from the amino acid sequence as set forth in SEQ ID NO: 1, wherein the at least two peptide monomers are each no longer than 30 amino acids, wherein the multimeric peptide is capable of reducing binding of Placenta Immunomodulatory Factor (PLIF) to human leukocytes.Type: ApplicationFiled: March 10, 2013Publication date: September 26, 2013Applicant: Ramot at Tel-Aviv University Ltd.Inventor: Chaya MOROZ
-
Publication number: 20130244927Abstract: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.Type: ApplicationFiled: February 15, 2012Publication date: September 19, 2013Inventors: Preeti Lal, Y. Tom Tang, Gina A. Gorgone, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Ingrid E. Akerblom, Janice Au-Young, Henry Yue, Chandra Patterson, Roopa Reddy, Jennifer L. Hillman, Olga Bandman
-
Patent number: 8530417Abstract: The present invention relates to granulocyte colony stimulating factor (G-CSF) modified with Y-shaped branched polyethylene glycol (YPEG-G-CSF) at a specific lysine (Lys 17) and the preparation thereof, as well as the pharmaceutical composition comprising YPEG-G-CSF and use thereof.Type: GrantFiled: December 29, 2007Date of Patent: September 10, 2013Assignee: Biosteed Gene Expression Tech Co. Ltd.Inventors: Shiyuan Wang, Jianhua Zheng, Li Sun, Huili Cai, Meihua Yang, Yan He, Ping Chen, Hongyuan Deng, Liping Zhong, Shuying Huang
-
Patent number: 8524240Abstract: The present invention relates to the field of diagnosis and therapy of hematological malignancies based on the tumor antigen FMR1NB (also called NY-SAR-35, Cancer/testis antigen 37 or Fragile X mental retardation 1 neighbor protein) and agents specifically targeting this antigen or cells expressing the same, e.g., antibodies. The inventors were able to prove that the molecule is expressed on the cell surface and thus represents a particularly advantageous target in cancer therapy and vaccination. Surprisingly, FMR1NB was found to be associated with hematological malignancies, e.g. acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).Type: GrantFiled: October 25, 2010Date of Patent: September 3, 2013Inventors: Djordje Atanackovic, Tim Luetkens
-
Patent number: 8524670Abstract: The present invention provides a novel CXCL12-?2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.Type: GrantFiled: November 30, 2010Date of Patent: September 3, 2013Assignees: Medical College of Wisconsin Research Foundation, The Rockefeller UniversityInventors: Brian F. Volkman, Christopher T. Veldkamp, Francis C. Peterson, Thomas Sakmar, Christoph H. Seibert
-
Publication number: 20130217633Abstract: A protease resistant polypeptide includes an amino acid sequence that has a sequence identity at least 80% homologous to about 10 to 80 consecutive amino acids of SEQ ID NO:1.Type: ApplicationFiled: September 1, 2011Publication date: August 22, 2013Applicant: CASE WESTERN RESERVE UNIVERSITYInventors: Clark Distelhorst, Yiping Rong
-
Patent number: 8501677Abstract: The present invention provides methods of reducing or enhancing T cell activation and/or B cell activation in a subject, comprising administering to a subject an effective amount of an inhibitor or enhancer, respectively, of Semaphorin 6D (Sema6D) activity on T cells and/or B cells.Type: GrantFiled: October 28, 2011Date of Patent: August 6, 2013Assignee: University of North Carolina at Chapel HillInventors: Jenny P.-Y. Ting, Brian P. O'Connor, So-Young Eun, Zhengmao Ye
-
Publication number: 20130196927Abstract: A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its cIAP degradation properties.Type: ApplicationFiled: January 28, 2013Publication date: August 1, 2013Inventors: Christopher BENETATOS, Srinivas CHUNDURU, Stephen CONDON, Mark McKINLAY, Yasuhiro MITSUUCHI
-
Publication number: 20130189256Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:Type: ApplicationFiled: January 29, 2013Publication date: July 25, 2013Applicant: Medarex, Inc.Inventor: Medarex, Inc.
-
Publication number: 20130190251Abstract: The present invention concerns a method for predicting the responsiveness of an individual suffering from leukemia to a chemotherapeutic drug. In particular, this method comprises determining the proportion of leukemic cells expressing cytoplasmic PCNA in a biological sample of the individual. The present invention also relates to a tyrosine kinase inhibitor for use for the treatment of an individual suffering from leukemia and having a proportion of leukemic cells expressing cytoplasmic PCNA in a biological sample lower than a predetermined threshold. The invention also pertains to a method for diagnosing whether an individual suffers, or is at risk of suffering, from leukemia.Type: ApplicationFiled: March 18, 2011Publication date: July 25, 2013Inventors: Veronique Witko-Sarsat, Didier Bouscary, Magali Pederzoli-Ribeil, Olivier Hermine, Isabelle Dusanter-Fourt
-
Publication number: 20130184201Abstract: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.Type: ApplicationFiled: March 6, 2013Publication date: July 18, 2013Applicants: Arizona State UniversityInventors: George R. Pettit, Rui Tan, Robin K. Pettit
-
Publication number: 20130184223Abstract: Disclosed are compositions and methods related to new targets for cancer treatment the modulation of autophagy.Type: ApplicationFiled: May 20, 2011Publication date: July 18, 2013Applicant: UNIVERSITY OF ROCHESTERInventors: Hartmut Land, Conan Kinsey
-
Publication number: 20130177558Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.Type: ApplicationFiled: October 4, 2012Publication date: July 11, 2013Applicant: BIOGEN IDEC MA INC.Inventor: Biogen Idec MA Inc.
-
Patent number: 8481497Abstract: [PROBLEMS] To provide a technique which enables an effective antibody therapy for cancer which targets for FGFR1 without the need of using any effective antibody having high specificity and a potent cell-killing activity. [MEANS FOR SOLVING PROBLEMS] Disclosed are: a therapeutic agent for cancer, which comprises an enhancer of the expression of a fibroblast growth factor receptor-1 and an anti-fibroblast growth factor receptor-1 antibody; and a method for the treatment of cancer using the therapeutic agent.Type: GrantFiled: May 29, 2008Date of Patent: July 9, 2013Assignees: Sapporo Medical University, The University of TokyoInventors: Kohzoh Imai, Shigeru Sasaki, Tsutomu Seito
-
Patent number: 8475794Abstract: Disclosed herein are compositions and methods of use comprising combinations of anti-CD74 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD74 antibody or may be separately administered, either before, simultaneously with or after the anti-CD74 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD74, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80, IL-6, CXCR4 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD74 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD74 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD74 antibody and therapeutic agent that are not conjugated to each other.Type: GrantFiled: August 15, 2011Date of Patent: July 2, 2013Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Publication number: 20130164218Abstract: This disclosure relates to Hypoxia Inducible Factor-1 pathway inhibitors and uses as anticancer and imaging agents. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions disclosed herein.Type: ApplicationFiled: December 27, 2012Publication date: June 27, 2013Applicant: EMORY UNIVERSITYInventor: EMORY UNIVERSITY
-
Publication number: 20130156727Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.Type: ApplicationFiled: November 21, 2012Publication date: June 20, 2013Applicant: Pharmacyclics, Inc.Inventor: Pharmacyclics, Inc.
-
Publication number: 20130156764Abstract: Disclosed herein are methods and compositions for treating leukemia and preventing leukemia relapse related to the administration of agents that inhibit the binding of FLT3 ligand to FLT3.Type: ApplicationFiled: March 14, 2011Publication date: June 20, 2013Applicant: The Johns Hopkins UniversityInventors: Mark J. Levis, Donald Small
-
Publication number: 20130157961Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.Type: ApplicationFiled: April 28, 2011Publication date: June 20, 2013Applicant: ESPERANCE PHARMACEUTICALS, INC.Inventors: Hector Alila, Carola Leuschner, Martha Juban, Ann Coulter
-
Patent number: 8466111Abstract: A cyclopenta[g]quinazoline derivative, containing an L-Glu-?-D-Glu dipeptide group, of formula (I): wherein R1 is amino, C1-4 hydroxyalkyl, C1-4 fluoroalkyl or methoxy-C1-4-alkyl; R2 is hydrogen, C1-4 alkyl, C3-4 alkenyl, C3-4 alkynyl, C2-4 hydroxyalkyl C2-4 halogenoalkyl or C1-4 cyanoalkyl; and Ar is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, C1-4 alkyl and C1-4 alkoxy, the compound (I) optionally being in the form of a pharmaceutically acceptable salt or ester; may be used for the treatment of rheumatoid arthritis or acute myeloid leukaemia.Type: GrantFiled: March 13, 2009Date of Patent: June 18, 2013Assignee: BTG International LimitedInventors: Gerrit Jansen, Ann Jackman
-
Patent number: 8461117Abstract: The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.Type: GrantFiled: December 28, 2007Date of Patent: June 11, 2013Assignee: Medarex, Inc.Inventors: Bilal Sufi, Vincent Guerlavais, Liang Chen, Sanjeev Gangwar, Qian Zhang, David B. Passmore
-
Publication number: 20130142867Abstract: Cancer-targeting peptides having a PX1LX2 motif, in which X1 is His or an amino acid residue with a hydrophobic side chain and X2 is Pro, Phe, or Trp. Also disclosed herein are conjugates containing the cancer-targeting peptides and uses thereof in cancer treatment and diagnosis.Type: ApplicationFiled: October 25, 2011Publication date: June 6, 2013Applicant: Academia SinicaInventors: John Yu, Alice L. Yu, H.C. Wu, I-Ju Chen, Sheng-Hung Wang
-
Publication number: 20130130992Abstract: This invention relates to purified compound of formula (1). The invention includes all isomeric forms and all tautomeric forms of the compound of formula (1) and pharmaceutically acceptable salts thereof. The present invention further relates to processes for the production of the compound of formula (1) by fermentation of the fungal strain of sterile mycelium (PM0509732/MTCC5544) and to pharmaceutical compositions containing the compound as active ingredient and its use in medicines for treatment of cancer.Type: ApplicationFiled: August 5, 2011Publication date: May 23, 2013Applicants: ONCOTEST GMBH, PIRAMAL ENTERPRISES LIMITEDInventors: Sunil Kumar Jaiwant Rao Deshmukh, Shilpa Amit Verekar, Prabhu Dutt Mishra, Sreekumar Sankaranarayanan Eyyammadichiyil, Kalpana Sanjay Joshi, Heinz-Herbert Fiebig, Gerhard Kelter
-
Publication number: 20130122046Abstract: Use of an ubiquitination pathway-related factor, its agonist or antagonist in the preparation of a composition for regulating FOXP3, IL-2, and/or IFN-? activity, in which the ubiquitination pathway-related factor is selected from: Toll-like receptor, ubiquitin ligase, pro-inflammatory cytokine family receptor, and/or its coding sequence. The new type of regulatory factors can regulate regulatory T cells and immune system by regulating FOXP3, IL-2, and/or IFN-? activity. The regulatory factors and their derivatives can also be used as immunoadjuvant for treating or preventing major diseases (such as, infectious diseases and tumor, etc).Type: ApplicationFiled: July 11, 2011Publication date: May 16, 2013Applicant: INSTITUT PASTEUR OF SHANGHAI, CASInventors: Bin Li, Fang Lin, Zuojia Chen, Zhiyuan Li, Fan Pan
-
Patent number: 8440630Abstract: The present invention is to provide a polypeptide specifically inhibiting the activity of Akt (Protein Kinase B), the DNA thereof, the antibody thereof, an inhibitor of Akt activity or an antitumor agent, and the like. The polypeptide comprises polypeptides (SEQ ID NO: 1, 3, 5, 7, and 9 of the sequence listing) that contain an amino acid sequence corresponding to any of the position of amino acid residue 10-24 of human TCL1, amino acid residue 8-22 of human TCL1B, amino acid residue 5-19 of human MTCP1, and amino acid residue 9-24 of mouse or rat TCL1; and the derivatives. Further, the present invention includes DNA encording the polypeptide (SEQ ID NO: 2, 4, 6, 8 or 10 of the sequence listing), and the antibodies specifically binding to the polypeptides. The polypeptide of the present invention can be used for an inhibitor of Akt activity, an antitumor agent, or the like.Type: GrantFiled: December 14, 2004Date of Patent: May 14, 2013Assignee: Japan Science and Technology AgencyInventors: Masayuki Noguchi, Futoshi Okada, Makoto Hiromura
-
Publication number: 20130115226Abstract: The present disclosure provides methods and uses of Tie2 binding and/or activating agents. In particular, the present disclosure provides methods and uses for inhibiting the expansion of colony forming unit-granulocytes, reducing eosinophils and/or basophils, for treating allergic disease or response or eosinophil/basophil associated condition and for reducing inflammatory cytokine and/or chemokine levels.Type: ApplicationFiled: April 28, 2011Publication date: May 9, 2013Applicant: Sunnybrook Health Sciences CentreInventors: Paul Van Slyke, Daniel Dumont
-
Publication number: 20130109619Abstract: A peptide or peptidomimetic comprising an amino acid sequence based on conserved regions of IL10 or IFN-gamma receptor sequences, and related compounds and compositions, as well as methods for the use thereof to inhibit cytokine signaling.Type: ApplicationFiled: May 11, 2011Publication date: May 2, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Nadya I. Tarasova, Giorgio Trinchieri, Howard A. Young, C. Andrew Stewart, Marco A. Cardone, Alan O. Perantoni
-
Patent number: 8410059Abstract: Therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt are described. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.Type: GrantFiled: July 8, 2011Date of Patent: April 2, 2013Assignee: Biokine Therapeutics Ltd.Inventors: Nobutaka Fujii, Hirokazu Tamamura, Akira Hori
-
Publication number: 20130071323Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.Type: ApplicationFiled: March 9, 2012Publication date: March 21, 2013Applicant: Gilead Calistoga LLCInventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Langdon Miller, Thomas M. Jahn
-
Publication number: 20130072421Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.Type: ApplicationFiled: January 13, 2011Publication date: March 21, 2013Applicant: CURNA, INCInventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
-
Publication number: 20130065816Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.Type: ApplicationFiled: November 2, 2010Publication date: March 14, 2013Applicant: The Administrators of the Tulane Educational FundInventors: David H. Coy, Jerome L. Maderdrut, Min Li
-
Publication number: 20130065827Abstract: The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions.Type: ApplicationFiled: April 6, 2011Publication date: March 14, 2013Inventor: Pasit Phiasivongsa
-
Publication number: 20130053303Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.Type: ApplicationFiled: October 5, 2012Publication date: February 28, 2013Applicant: Onyx Therapeutics, Inc.Inventor: Onyx Therapeutics, Inc.
-
Publication number: 20130045214Abstract: Methods of screening for modulators of TRIM24 (also known as TIF1-ALPHA) expression and/or biological activity are described. In particular, methods of screening for modulators of TRIM24 E3 ligase activity, and specifically an E3 ligase activity directed at p53 as the target polypeptide are also described. Modulators of TRIM24 expression and activity are provided and their use in treatment of cancer, particularly in breast, colon, prostate, renal cancers and in acute lymphoblastic leukemia. Suitable modulators of TRIM24 expression include siRNA and shRNA and can be used in the treatment of cancer and for targeting cancer stem cells.Type: ApplicationFiled: June 25, 2012Publication date: February 21, 2013Inventor: Michelle Barton
-
Patent number: 8377883Abstract: The present invention relates to a peptide for anti-angiogenesis and use thereof, in particular, to a peptide useful for treating angiogenesis diseases; a polynucleotide coding the peptide; a vector and a cell comprising the polynucleotide; a pharmaceutical composition comprising the peptide, the fused peptide or the fused protein, the polynucleotide, the vector and/or the cell. The peptide, the fused peptide or the fused protein, the polynucleotide, the vector, the cell and/or the pharmaceutical composition can be used for treatment of associated diseases such as tumor by anti-angiogenesis.Type: GrantFiled: September 29, 2007Date of Patent: February 19, 2013Assignee: Beijing Institute for Cancer ResearchInventors: Chengchao Shou, Yahui Su, Qin Feng
-
EFFICIENT SYNTHESIS OF CHELATORS FOR NUCLEAR IMAGING AND RADIOTHERAPY: COMPOSITIONS AND APPLICATIONS
Publication number: 20130039853Abstract: Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.Type: ApplicationFiled: July 31, 2012Publication date: February 14, 2013Inventors: David J. Yang, Dongfang Yu, Andrew S. Thompson, F. David Rollo -
Publication number: 20130017996Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: September 14, 2012Publication date: January 17, 2013Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Publication number: 20130013334Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.Type: ApplicationFiled: August 31, 2012Publication date: January 10, 2013Applicant: Millennium Pharmaceuticals, Inc.Inventors: Barbara M. Bryant, Andrew I. Damokosh, George Mulligan
-
Publication number: 20130005645Abstract: The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed.Type: ApplicationFiled: January 6, 2011Publication date: January 3, 2013Inventors: Michael P. VITEK, Dale J. Christensen
-
Publication number: 20120328619Abstract: The present invention relates to a molecule having binding specificities for (a) CD123; (b) CD16 and (c) CD33. The present invention further relates to the molecule of the invention, wherein the molecule comprises a first immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to CD123; a second immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to CD16; and a third immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to CD33. The present invention furthermore relates to a nucleic acid molecule encoding the molecule of the invention. In addition, the present invention relates to diagnostic and pharmaceutical compositions and the use of the molecule or the nucleic acid molecule of the invention in the treatment of acute myeloid leukaemia and/or myelodysplastic syndrome.Type: ApplicationFiled: December 9, 2010Publication date: December 27, 2012Inventors: Georg H. Fey, Christoph Stein, Christian Kellner, Markus Kügler
-
Publication number: 20120322742Abstract: Cell permeable peptides derived from MLL that block the interaction of MLL with menin for the treatment of acute myeloid and acute lymphoid leukemia are disclosed. Small molecules interfere with the interaction of MLL with any of its binding partners.Type: ApplicationFiled: July 18, 2012Publication date: December 20, 2012Applicant: THE UNIVERSITY OF CHICAGOInventor: Michael J. Thirman
-
Publication number: 20120316101Abstract: The present invention relates to a polypeptide capable of specifically targeting apoptotic cells undergoing apoptosis and a use thereof. More particularly, it relates to an isolated polypeptide consisting of the sequence (I): Cys-X1-Val-Ala-Pro-X2 (I), wherein X1 is an amino acid with polar uncharged side chain and X2 is an amino acid with positive charged side chain and targeting apoptotic cells, a composition for detection of apoptotic cells comprising the same as an effective ingredient, a composition for drug delivery comprising the same as an effective ingredient, a composition for imaging comprising the same as an effective ingredient and the like. Accordingly, the peptide of the present invention may be useful for detection of apoptotic cells, as well as detection and imaging of apoptotic cells in tumor tissue, apoptotic myocardial cells in myocardial infarction tissue, apoptotic nerve cells in stroke tissue and arteriosclerosis site, and targeted drug delivery thereto.Type: ApplicationFiled: May 9, 2012Publication date: December 13, 2012Applicant: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Byung Heon Lee, In San Kim
-
Patent number: 8329657Abstract: Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer.Type: GrantFiled: August 11, 2011Date of Patent: December 11, 2012Assignee: The Trustees of the University of PennsylvaniaInventors: Mark L. Tykocinski, Marjaneh Razmara
-
Patent number: 8329861Abstract: Provided is a novel, isolated polypeptide including an amino acid sequence of SEQ. ID. NO: 2 or SEQ. ID. NO: 4, and the nucleic acid molecule which encodes it. The polypeptide may be used in a method for treating various diseases including cancer, immune associated, viral and inflammatory diseases.Type: GrantFiled: December 25, 2008Date of Patent: December 11, 2012Assignee: Two To Biotech Ltd.Inventors: Tamar Sandler, Orly Devary
-
Publication number: 20120308646Abstract: Aminoside tetracyclic anthraquinones represented by formula (I) and (II). Peptides are introduced to connect tetracyclic anthraquinones and fatty acid to enable selective absorption and release of the anticancer agents. In addition, aminosaccharide and tetracyclic moieties are introduced into the branched chain to improve water-solubility. The compounds of formula (I) and (II) are pharmaceutically active components useful for treating diseases that are cured by aminoside tetracyclic anthraquinones, including cancer.Type: ApplicationFiled: August 13, 2012Publication date: December 6, 2012Inventor: Hesheng ZHANG
-
Publication number: 20120309938Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.Type: ApplicationFiled: February 3, 2012Publication date: December 6, 2012Applicant: EISAI CO., LTD.Inventors: James J. KOWALCZYK, Galina KUZNETSOV, Shawn SCHILLER, Boris M. SELETSKY, Mark SPYVEE, Hu YANG
-
Publication number: 20120302503Abstract: Described herein are therapeutic peptides composed of a cell penetrating peptide, a peptide derived from the sequence of c-Myb, and a peptide derived from the sequence of CREB, useful for the treatment or prevention of a disease or disorder associated with CBP or p300 misregulation.Type: ApplicationFiled: May 7, 2012Publication date: November 29, 2012Applicant: AML Therapeutics, LLCInventor: Mark R. Hurtt
-
Publication number: 20120302510Abstract: The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell proliferation and differentiation in vitro and in vivo.Type: ApplicationFiled: August 3, 2012Publication date: November 29, 2012Applicant: President and Fellows of Harvard CollegeInventors: Stuart L. Schreiber, Jack Taunton, Christian A. Hassig, Timothy F. Jamison
-
Publication number: 20120302511Abstract: Provided are peptides that bind to the thymidylate synthase protein, in particular to human thymidylate synthase (hTS) protein, for the treatment of cancer. Further provided are peptides that can bind at a binding site located at the interface of thymidylate synthase protein. These peptides range from 3 to 10, preferably 4-8 amino acids and have a sequence that binds to each subunit of the thymidylate synthase dimer at the level of dimer interface, stabilizing the dimeric inactive form of the thymidylate synthase enzyme. In addition, provided are pharmaceutical compositions including these compounds as active agents, and uses thereof for the treatment of cancer and to reverse or/and be active in cancer drug resistance.Type: ApplicationFiled: December 1, 2009Publication date: November 29, 2012Inventors: Maria Paola Costi, Gaetano Marverti, Daniela Cardinale, Alberto Venturelli, Stefania Ferrari, Glauco Ponterini, Stefan Henrich, Outi Salo-Ahen, Rebecca Wade